Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Early completion anticipated for pivotal R-1549 trial

July 21, 2003

MEDI-507 proven effective in a murine model of adult T-cell leukemia

July 15, 2003

MDX-010 combined with tumor vaccines in metastatic melanoma

July 14, 2003

Multikine may enhance success of radiation and chemotherapy in H&N cancer

July 11, 2003

HuMax-CD20 effective in depleting B-cells in primate study

July 10, 2003

Alemtuzumab reported to increase clinical response and remission in refractory CLL

July 8, 2003

Treatment begins in INGN-225 phase I/II study

July 7, 2003

Phase II trial to evaluate Pentrix in prostate cancer

July 4, 2003

Antisoma initiates enrollment in phase I study of R-1550 in breast cancer

July 4, 2003

Preclinical studies support use of MT-103 for chronic lymphocytic leukemia

July 1, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...